The surface of Au-SPEs was digested with TCEP, and the eluted solution was tested using a NanoDrop spectrophotometer (Thermofisher Scientific Inc, Waltham, MA, USA) to measure the absorbance

The surface of Au-SPEs was digested with TCEP, and the eluted solution was tested using a NanoDrop spectrophotometer (Thermofisher Scientific Inc, Waltham, MA, USA) to measure the absorbance. To evaluate the efficiency of the developed PEG-based site-directed conjugation approach, we tested the presence of antibodies about the surface of Au-SPEs using multiple techniques, including colorimetry, fluorometry, Ultraviolet-visible (UV-Vis), Fourier-transform infrared (FTIR) spectroscopy, and sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis [44]. resistance (AMR) screening, our results demonstrate a ~10-collapse increase in antibody coupling Enfuvirtide Acetate(T-20) compared with the standard N-hydroxysuccinimide (NHS)-centered conjugation chemistry and effective capture (>94%) of the prospective KPC-2 enzyme antigen on the surface of altered electrodes. This straightforward and easy-to-perform strategy of site-directed antibody conjugation can be designed for Enfuvirtide Acetate(T-20) coupling additional protein- and non-protein-based biological molecules commonly used in POC screening and development, therefore enhancing the potential for improved diagnostic accuracy and overall performance. Keywords: biological molecules, antibody, directional, site-specific, controlled, conjugation, immunoassay, screen-printed electrodes, point of care 1. Intro The demand for point-of-care (POC) medicine is rapidly increasing in our modernized and globalized world. POC diagnostics have revolutionized healthcare by providing quick and accurate disease analysis at the individuals bedside or inside a medical setting [1]. Immunoassays are widely used in POC diagnostics for detecting analytes such as proteins, nucleic acids, and small molecules [2]. However, the level of sensitivity and specificity of immunoassays are limited by the availability and orientation of the antibodies on the surface of the assay platform [3]. Standard conjugation methods involve random and non-specific chemical reactions between the antibody and the conjugation partner, such as N-hydroxysuccinimide (NHS) ester or maleimide chemistry, which can result in low yields, heterogeneous products, and reduced antibody activity [4,5]. Site-specific changes strategies have been developed to overcome limitations by enabling the selective conjugation of antibodies to specific sites and improving the availability and orientation of the antibodies on the surface of the assay platform [6,7,8,9,10,11,12,13]. Chemical conjugation using practical polymers such as polyethylene glycol (PEG) offers emerged as a superior alternative to traditional conjugation methods [14]. PEG can be very easily conjugated to antibodies through numerous chemistries and offers several advantages compared to additional polymers, including high water solubility, low toxicity, and low immunogenicity [15,16,17]. Moreover, PEG conjugation can enhance the stability and shelf-life of the antibody, increase the solubility and bioavailability of the conjugate, and reduce the clearance rate from the body [18,19,20]. These properties make PEG an ideal candidate for conjugation with antibodies in POC diagnostics. Point-of-care diagnostics have been a game-changer in infectious disease control, providing rapid, patient-centric screening with immediate results. The importance of such quick diagnostic tools has been highlighted in recent global health crises, such as the COVID-19 pandemic. PEGylated antibodies have been employed in lateral circulation immunoassays (LFIs) for the detection of KLRC1 antibody SARS-CoV-2 antigens [21]. The stability of these PEGylated antibodies allows the LFIs to deliver quick, point-of-care diagnostics in varied settings, potentially contributing to common pandemic control. The PEGylation process has proved particularly beneficial for the detection of antigens that are usually present at low concentrations in the early stages of illness, making them demanding for traditional immunoassays to identify. PEGylated antibodies, because of the enhanced stability and activity, can bind to these low-concentration antigens and generate a stronger and more detectable transmission [22]. This improved level of sensitivity and specificity offered by PEGylated antibodies takes on a critical part in early disease detection, leading to timely treatment and better Enfuvirtide Acetate(T-20) patient results. Furthermore, PEGylated antibodies have found power in the detection of bacterial infections. The use of PEGylated antibodies in LFIs has been effective in diagnosing infections caused by MRSA, Tuberculosis (TB), streptococcus pneumoniae and staphylococcus aureus [23,24,25,26]. By improving the detection limit and specificity of these immunoassays, PEGylated antibodies have bolstered the medical utility of these diagnostic tools. PEGylation also takes on a crucial part in enhancing the stability of biosensors utilized for infectious disease analysis. For instance, PEGylated antibodies have been immobilized on the surface of electrochemical biosensors, leading to a significant improvement in the detection of the hepatitis B surface agent [27]. PEGylation reduced nonspecific binding, therefore improving the biosensors level of sensitivity and reliability. One of the major advantages of chemical conjugation using practical polymers like PEG is definitely that it enables site-specific changes for antibody conjugation [28,29,30]. These methods have gained significant attention in the development of POC diagnostics. PEG enables the selective and controlled conjugation of antibodies to specific sites, reducing the risk of antibody denaturation and loss of function [31]. Moreover, PEG conjugated antibodies present enhanced overall performance and accuracy in immunoassays by improving the availability and orientation of the antibodies within the assay platform. Here, we present a novel approach for PEG-mediated site-specific antibody conjugation for the development of a POC-based electrode microchip.